1 / 22

Sympathetic Drugs

Sympathetic Drugs. Stress and The Adrenal Glands. Adrenal Medulla: A Modified Sympathetic Ganglion. Mechanism: Norepinephrine Release and Recycling. Review of Efferent Pathways: Motor and Autonomic. Catechalomines: Activity. Stimulates the “fight or fight” reaction

Télécharger la présentation

Sympathetic Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. Sympathetic Drugs

  2. Stress and The Adrenal Glands

  3. Adrenal Medulla: A Modified Sympathetic Ganglion

  4. Mechanism: Norepinephrine Release and Recycling

  5. Review of Efferent Pathways: Motor and Autonomic

  6. Catechalomines: Activity • Stimulates the “fight or fight” reaction • Increased plasma glucose levels • Increased cardiovascular function • Increased metabolic function • Decreased gastrointestinal and genitourinary function

  7. Activity of Epinephrine

  8. Sympathomimetics • Drugs that partially or completely mimic the actions or norepinephrine (NE) and epinephrine (Epi). • Act either - directly on α- and/or β- adrenoceptors or indirectly on presynaptic terminals, usually by causing the release of NE. • See Below

  9. β2-Adrenoceptor Agonists – cause bronchial dilation - used for the treating asthma, prevent pre-term labor (relaxing uterine muscle). • β1-Adrenoceptor Agonists – (e.g., dobutamine) sometimes used to increase the force of heart contraction in severe low-output heart failure. • α1-Agonists – (e.g., phenylephrine) – used as mydriatics, decongestants. • α2-Agonists – (e.g., clonidine, methyldopa) – centrally acting hypotensive drugs.

  10. Sympathomimetics act mainly by causing release of NE (e.g., amphetamine) have the α1/α2 selectivity of NE. • β-Adrenoceptor antagonists (β-blockers) – used to treat hypertension, angina, cardiac arrhythmias, CHF, and glaucoma. • α-Adrenoceptor antagonists (α-blockers) – limited clinical application – prazosin (selective α1-antagonist – used to treat hypertension. • Adrenergic neuron blocking drugs – either deplete the nerve terminals of NE or prevent its release – used as hypotensive agents.

  11. Metabolism of Norepinephrine

  12. Reuptake • Monoamine Oxidase • Catechol-O-methytransferase (COMT) • α1-Adrenoceptors – in several tissues (e.g., smooth muscle, salivary glands) incr IP3 and [Ca2+]in vasoconstriction or glandular secretion • α2-Adrenoceptors – on noradrenergic nerve terminals. Activation by NE inhibit AC, decrcAMP, Ca2+ channels close decr further nt release. • β-Adrenoceptor – stim AC incr [cAMP]  2nd messenger intracellular signaling physiol response.

  13. Indirectly-Acting Sympathomimetics • Transported into nerve terminals where they displace vesicular NE into the cytoplasm. Some is metabolized by MAO, but the remainder is released by carrier-mediated transport to activate adrenoceptors. • Amphetamines – resistant to MAO. - Peripheral actions - tachycardia, hypertension - mainly caused by catecholamine release. - Dexamfetamine and methylphenidate used for hyperactive children. • Cocaine – NE reuptake inhibitor (also dopamine) – Intense central stimulant  popular drug of abuse.

  14. Acute and chronic effects of Indirectly acting sympathomimetics G = Guanethidine

  15. Mechanism of action of cocaine and reserpine

  16. Directly-Acting Sympathomimetics • Effects in humans depends on their receptor specificity (αand/or β) and on the compensatory reflexes they evoke. • Epiincrbp by stim the rate and force of the heart beat (β1 effects). • Stimulation of vascular α-receptors causes vasoconstriction (viscera, skin), whereas…, • Stimulation of vascular β2-receptors vasodilation (skeletal muscle) … • And the total peripheral resistance may actually decrease. • NE has little-to-no effect on the vascular β2-receptors; thus, the α-mediated vasoconstriction is unopposed. • The resulting rise in bp reflexively slows the heart, usually overcoming the direct β1-stimulant action on the heart rate.

  17. β-Receptor-Selective Drugs • Isoprenaline – stimulates all β-receptors incr rate and force of heart beat and vasodilation full diastole and MAP, with little change in systolic pressure. • β2-Adrenoceptor Agonists – relatively selective class of drugs that produce bronchodilation – used for asthma (resistant to MAO, not uptaken into neurons).

  18. Adrenoceptor Antagonistsα-Blockers • Decrartiolar and venous tone decr peripheral resistance  hypotension. • Reverse the pressor effects of Epi, because its β2-mediated vasodilator effects are unopposed by α-mediated vasoconstriction  peripheral resistance falls (Epi reversal). • Cause reflex tachycardia – this is greater with non-selective drugs that also block α2-presynaptic receptors on the heart, because the augmented release of NE further stimulates the cardiac β-receptors (e.g., prazosin).

  19. Adrenoceptor Antagonistsβ-Blockers • Vary in lipid solubility and cardioselectivity • All block β1-receptors and decrbp and prevent angina. • Higher Kow-drugs  more rapid absorption from GIT, 1st-pass hepatic elimination  more rapidly eliminated. • Also more likely to enter CNS and cause central effects (e.g., nightmares). • Cardioselectivity diminishes with higher doses.

  20. Adrenoceptor Antagonistsβ-Blockers (Cont’d) • Nevertheless, selective β1-blockade  less peripheral vasoconstriction (cold hands and feet) and does not reduce the response to exercise-induced hypoglycemia (stim of gluconeogenesis in liver is mediated by β2-receptors). • Cardioselective drugs may have sufficient β2-activity to ppt severe bronchospasms in patients with asthma – these patients should avoid β-blockers . • Some possess intrinsic sympathomimetic activity (partial agonists), but this is debatable.

  21. Catecholamine synthesis, storage, release, and reuptake pathways

More Related